Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| KD | Kyndryl | $10.50 | -$12.99 | -55.30% | 728.7K | $5.4B | $10.11$44.20 |
| PLYX | Polaryx Therapeutics | $6.40 | -$2.51 | -28.17% | 92.3K | $422M | $2.51$48.91 |
| FLYE | Fly-E Group | $2.54 | -$0.92 | -26.59% | 12.5K | $5.6M | $2.50$161.80 |
| VHUB | VenHub Global | $3.57 | -$1.26 | -26.07% | 371.7K | $362M | $3.40$40.30 |
| PFSA | Profusa | $3.25 | -$1.12 | -25.67% | 216.5K | $378M | $3.10$957.00 |
| HIMS | Hims & Hers Health | $17.57 | -$5.45 | -23.68% | 2.6M | $5.2B | $16.36$72.98 |
| MNDY | Monday.com | $76.20 | -$21.80 | -22.25% | 303K | $5.0B | $73.01$342.64 |
| RDIB | Reading International | $10.60 | -$2.86 | -21.25% | 23.9K | $306M | $5.81$17.40 |
| PGY | Pagaya Technologies | $15.02 | -$3.62 | -19.42% | 16.5M | $1.5B | $8.50$44.99 |
| MPAA | Motorcar Parts Of America | $10.66 | -$2.48 | -18.87% | 8.2K | $257M | $6.04$18.12 |
| SMX | Smx (Security Matters) Public | $12.91 | -$2.92 | -18.45% | 3.2M | $138M | $3.12$9,134.28 |
| CLF | Cleveland-Cliffs | $12.02 | -$2.72 | -18.43% | 32.1M | $8.4B | $5.63$16.70 |
| SXTC | China Sxt Pharmaceuticals | $2.45 | -$0.55 | -18.35% | 4.3M | $2.6M | $2.34$1,176.00 |
| MAXN | Maxeon Solar Technologies | $3.34 | -$0.55 | -14.14% | 7.5K | $66M | $2.46$6.02 |
| PLTZ | Tidal Trust II - Defiance Daily Target 2x Short Pltr ETF | $32.84 | -$4.94 | -13.08% | 1.4M | - | $19.91$75.28 |
| FCUV | Focus Universal | $5.90 | -$0.79 | -11.81% | 288.2K | $55M | $5.00$61.40 |
| NNNN | Anbio Biotechnology | $22.71 | -$2.94 | -11.46% | 210 | $1.1B | $5.00$55.65 |
| IBG | Innovation Beverage Group | $4.41 | -$0.37 | -7.74% | 24K | $3.3M | $3.27$49.25 |
Related Articles
Featured Article
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Monday.com Stock Is Crashing. Time to Buy the Dip?
Timothy Green|Nov 10, 2025
The software company's slight guidance cut tanked the stock.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
1 Growth Stock Down 30% You Don't Want to Miss On
Neil Rozenbaum|Oct 6, 2025
The recent pullback is a blessing in disguise.
Cleveland-Cliffs Stock Just Keeps Dropping. Buying Opportunity, or a Sign to Steer Clear?
Reuben Gregg Brewer|Oct 1, 2025
Cleveland-Cliffs is losing money as the steel industry deals with a downturn, which is exactly why you might want to buy it.
A Healthcare Debate: Progyny vs. Hims & Hers
Motley Fool Staff|Sep 26, 2025
Motley Fool analysts take a look.
